By Chermaine Lee
Imagine this: if your beloved one was diagnosed of a fatal cancer, dealing with heartbreaks aside, you had to start borrowing money for the treatment. Taking a few more part-time jobs was barely enough to pay for the expensive drugs, not to mention the ever-growing debts.
By Alfred Romann
The backlash against global trade and the resurgence of protectionism is increasingly evident, mostly out of the U.S. This push flies in the face of decades of increasingly fluent globalization.
New measures put pressure on drug makers, importers and distributors
South Korea’s latest moves to make drugs more affordable are slowing down the growth of the pharma market in the country and maybe hurting sales of new and innovative drugs.
BMI Research predicts South Korean pharmaceutical will grow at 2.4% for the next 10 years, 1% less than expected. Elise Mak wrote about the changes in BioWorld (paywall) on May 4.
11 December 2015
Mexico becomes first country to approve new vaccine, 20 others to follow
It has been a long time coming, but the first dengue vaccine should hit the market next year in Mexico and, with any luck, in about 20 markets over the next couple of years.
The Philippines could be next.
17 September 2015
Companies are narrowing the gap
China is not a powerhouse of innovation, yet, but it is certainly trying to pay its way into that particular status. This willingness to spend in R&D – to pay to talent, buy innovative companies and seek out new technologies – is particularly visible in the pharmaceutical and biotechnology space. And it is working.
Australia’s life science sector outperforms in research… falls short on commercialisation.
It is no surprise that the life science sector including pharmaceutical, medical devices etc. is one of the hottest investment destinations. Last month, Australian investment company Brandon Capital closed the largest life science fund to date in Australia after raising A$200 million (US$155 million). The fund is set to fill the funding gap of the country’s medical technology commercialisation.
A long-awaited set of guidelines for a billion-dollar market.
After years of waiting, Chinese biosimilar makers will soon have a set of guidelines to follow.
This post on Thomson Reuters Life Sciences Connect news blog (HERE) outlines the industry’s reaction to the draft biosimilar guidelines.